Adams execs
This article was originally published in The Tan Sheet
Executive Summary
Helmut Albrecht, MD, joins Adams Respiratory Therapeutics to serve as senior VP-R&D, the firm announces Oct. 29. Albrecht will oversee all R&D activities, including clinical development, regulatory issues and new product development; the new exec said Adams "is ready to expand its presence in the respiratory category." Most recently, Albrecht was Novartis Consumer Health/OTC business unit's VP-global preclinical & clinical development. New VP-Regulatory Affairs Susan Witham will report to Albrecht. Witham previously held senior positions at J&J Consumer and Novartis. The appointments follow Adams' recently announced strategic decision to focus on OTCs and expand the Mucinex line (1"The Tan Sheet" May 31, 2004, p. 9)...
You may also be interested in...
Mucinex Line Extensions Underscore Adams’ Commitment To Building OTCs
A major task facing Adams Respiratory Therapeutics' new VP-OTC Marketing & Business Development Robert Casale will be to plan a Fall 2004 launch of extensions to the firm's Mucinex expectorant brand
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.